Project Grant W81XWH1610463

This $8.7 million project grant from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), supports the development of patient care technologies for permanent ambulatory artificial lung support from May 2022 to April 2026. Carnegie Mellon University is the primary awardee and will develop technologies to transition a pulmonary assist system to long-term support of chronic lung disease patients. Vanderbilt University Medical...

The Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $2,172,212.00 project grant to the University of California, Santa Barbara (UCSB) to develop a biomimetic, self-deploying intubation device for safer and more effective airway management in austere, far-forward environments. UCSB has engaged Vine Medical Inc. and Stanford University as sub-awardees to collaborate on this multi-year (Sep 2023 - Sep 2025) research and development effort. The...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...

Federal Project Grant Award Summary Weill Medical College of Cornell University received a $791,503 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with completion targeted for June 30, 2029. This research initiative investigates novel roles of the thrombin receptor Protease Activated Receptor-1 (PAR1) in lung lymphatic function and acute respiratory distress syndrome (ARDS)....

This Project Grant from the National Science Foundation's Division of Industrial Innovation, under the Engineering program (CFDA 47.041), provides $256,000 to Colabs, Inc. to develop an automated airway and ventilator system that eliminates human operator variability during cardiopulmonary resuscitation (CPR). The system aims to reliably place an airway tube for ventilation, synchronize air delivery with chest compressions, and enable cardiac defibrillation at lower voltages through an electrode...

This $2,623,234 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports the development of a wearable multiplex biosensor system to monitor exacerbation risk in patients with chronic obstructive pulmonary disease (COPD). The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center is the prime awardee, collaborating with researchers at the California Institute of Technology...

Federal Project Grant Summary Respair, Inc. received a $305,218 award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate AssuranceET, a novel pediatric endotracheal tube (ETT) designed to improve airway sealing while reducing trauma risk. The award, obligated on September 15, 2025, with an ultimate completion date of August 31, 2026, supports a Small Business Innovation Research (SBIR) Phase I...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant awarded $274,440 to Vine Medical Inc., a for-profit manufacturing company, to develop a proof-of-concept for a self-deploying endotracheal intubation device. The proposed soft robotics system aims to achieve over a 90% first-pass intubation success rate, which would improve patient outcomes and reduce complications during emergency airway management procedures. The device is designed to...

This Project Grant award of $409,792, provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research to develop a highly penetrating nanodisc for targeting fibroblast plasticity in pulmonary fibrosis. The project will evaluate the efficacy of these nanodiscs in human lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients and in a mouse model of pulmonary fibrosis. The award recipient is Brigham & Women's Hospital...

This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...